NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
4
Data completeness
5/8 — Partial
LASTACAFT (alcaftadine) by AbbVie is histamine h1 receptor antagonists [moa]. First approved in 2010.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASTACAFT (alcaftadine) is a selective histamine H1 receptor antagonist ophthalmic solution approved for allergic conjunctivitis. It works by blocking histamine-mediated allergic responses in the eye, providing rapid relief of itching and ocular symptoms. The drug is administered as eye drops for topical ocular use.
LOE Approaching1.5 years to LOE
Product approaching loss of exclusivity with moderate competitive pressure; brand team focus will shift toward lifecycle extension strategies and cost management.
Mechanism of Action
Histamine H1 Receptor Antagonists
Pharmacologic Class:
Histamine-1 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
Started Oct 2015
3,423 enrolled
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
Started Nov 2012
157 enrolled
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
Started Oct 2011
127 enrolled
Conjunctivitis, Allergic
A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
Started Apr 2011
25 enrolled
Allergic Conjunctivitis
Worked on LASTACAFT at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.